27.37 0.17 (0.63%) | 11-29 13:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 37.71 | 1-year : | 44.05 |
Resists | First : | 32.29 | Second : | 37.71 |
Pivot price | 26.18 | |||
Supports | First : | 25.59 | Second : | 21.45 |
MAs | MA(5) : | 26.42 | MA(20) : | 25.83 |
MA(100) : | 25.45 | MA(250) : | 26.78 | |
MACD | MACD : | 0.5 | Signal : | 0.4 |
%K %D | K(14,3) : | 39.7 | D(3) : | 38.9 |
RSI | RSI(14): 57.4 | |||
52-week | High : | 49.5 | Low : | 20.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BEAM ] has closed below upper band by 33.2%. Bollinger Bands are 4.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 27.32 - 27.45 | 27.45 - 27.57 |
Low: | 25.76 - 25.91 | 25.91 - 26.05 |
Close: | 26.95 - 27.19 | 27.19 - 27.41 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Sun, 01 Dec 2024
Bellevue Group AG Acquires 100,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Sat, 30 Nov 2024
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wed, 27 Nov 2024
Beam Therapeutics (BEAM) Stock Surges Over 5% Amid Positive Indu - GuruFocus.com
Wed, 06 Nov 2024
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance
Tue, 05 Nov 2024
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 83 (M) |
Shares Float | 65 (M) |
Held by Insiders | 1.4 (%) |
Held by Institutions | 93.1 (%) |
Shares Short | 12,310 (K) |
Shares Short P.Month | 11,360 (K) |
EPS | -1.59 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 9.97 |
Profit Margin | -41.1 % |
Operating Margin | -746.5 % |
Return on Assets (ttm) | -9.3 % |
Return on Equity (ttm) | -18.3 % |
Qtrly Rev. Growth | -17 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 4.22 |
EBITDA (p.s.) | -1.95 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -136 (M) |
Levered Free Cash Flow | -39 (M) |
PE Ratio | -17.33 |
PEG Ratio | 0 |
Price to Book value | 2.74 |
Price to Sales | 6.48 |
Price to Cash Flow | -16.69 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |